Form 4 for GILD Gilead Sciences
Accepted 2025-03-12 00:00:00 ET · period of report 2025-03-10 · accession 0001127602-25-009283 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-03-12 | 2025-03-10 | GILD | Dickinson Andrew D | CFO | S - Sale+OE | $118.17 | -17.9K | 182.1K | -9% | -$2.12M |
| DM | 2025-03-12 | 2025-03-10 | GILD | Dickinson Andrew D | CFO | M - OptEx | $63.91 | +25.9K | 187.0K | +16% | +$1.66M |
| D | 2025-03-12 | 2025-03-10 | GILD | Dickinson Andrew D | CFO | F - Tax | $117.21 | -3,855 | 173.2K | -2% | -$451.8K |
| DM | 2025-03-12 | 2025-03-10 | GILD | Dickinson Andrew D | CFO | M - OptEx | $0.00 | -25.9K | 0 | -100% | $0 |
| DM | 2025-03-12 | 2025-03-10 | GILD | Dickinson Andrew D | CFO | A - Grant | $0.00 | +60.1K | 38.6K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-10 | S | D | 13,013 | $118.50 | 169,061 | D | — | — | (F3) Sale prices reported for the transactions reported here range from $118.00 to $118.80. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. |
| 2 | Common | Common Stock | 2025-03-10 | M | A | 7,968 | — | 177,029 | D | — | — | (F4) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| 3 | Common | Common Stock | 2025-03-10 | S | D | 4,916 | $117.30 | 182,074 | D | — | — | (F2) Sale prices reported for the transactions reported here range from $116.97 to $117.88. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. |
| 4 | Common | Common Stock | 2025-03-10 | M | A | 4,916 | $63.91 | 173,977 | D | — | — | |
| 5 | Common | Common Stock | 2025-03-10 | M | A | 13,013 | $63.91 | 186,990 | D | — | — | |
| 6 | Common | Common Stock | 2025-03-10 | F | D | 3,855 | $117.21 | 173,174 | D | — | — | |
| 7 | Derivative | Non-qualified Stock Option (Right to Buy) | 2025-03-10 | M | D | 4,916 | $0.00 | 13,013 | D | $63.91 · — to 2031-03-10 | 4,916 Common Stock | (F5) The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 8 | Derivative | Restricted Stock Unit | 2025-03-10 | M | D | 7,968 | — | 27,519 | D | — · — to — | 7,968 Common Stock | (F4) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F6) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 9 | Derivative | Non-qualified Stock Option (Right to Buy) | 2025-03-10 | A | A | 49,020 | $0.00 | 49,020 | D | $117.21 · — to 2035-03-10 | 49,020 Common Stock | (F5) The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 10 | Derivative | Non-qualified Stock Option (Right to Buy) | 2025-03-10 | M | D | 13,013 | $0.00 | 0 | D | $63.91 · — to 2031-03-10 | 13,013 Common Stock | (F5) The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 11 | Derivative | Restricted Stock Unit | 2025-03-10 | A | A | 11,090 | — | 38,609 | D | — · — to — | 11,090 Common Stock | (F4) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F6) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |